Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials

  • Authors:
    • Chengyao Zhang
    • Jiawu Wang
    • Haitao Gu
    • Daihua Zhu
    • Yang Li
    • Peng Zhu
    • Yaxu Wang
    • Jijian Wang
  • View Affiliations

  • Published online on: January 16, 2012     https://doi.org/10.3892/ol.2012.567
  • Pages: 831-838
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

The aim of this study was to evaluate the curative effects and safety of capecitabine plus oxaliplatin compared with 5-fluorouracil (5-FU) plus oxaliplatin in patients with metastatic colorectal cancer (MCRC). We searched the Cochrane Central register of Controlled Trials (CENTRAL), PubMed, Ovid, ScienceDirect, EBSCO, EMBASE and conference proceedings for eligible trials. A meta-analysis was performed using Review Manager 5.0. A total of 3,603 cancer patients from 7 trials were analyzed, and the baseline patient characteristics were comparable in all studies. Curative effect outcomes including complete response (CR) (OR=0.78; 95% CI 0.47-1.31; p=0.35), partial response (PR) (OR=0.81; 95% CI 0.65-1.00; p=0.05) and the overall response rate (ORR) (OR=0.85; 95% CI 0.71-1.02; p=0.08) showed similar curative effects between the capecitabine plus oxaliplatin group and the 5-FU plus oxaliplatin group. Moreover, the median overall survival (OS) and progression-free survival (PFS) had no statistically significant differences. Regarding safety, hand-foot syndrome was more frequently observed in the capecitabine plus oxaliplatin group (OR=2.71; 95% CI 2.04-3.61; p<0.00001), while stomatitis and neutropenia were reversed. Other toxic effects had no statistically significant differences between the two groups. Our results showed that capecitabine plus oxaliplatin had similar curative effects to 5-FU plus oxaliplatin, however, it was safer in patients with MCRC.

Related Articles

Journal Cover

April 2012
Volume 3 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhang, C., Wang, J., Gu, H., Zhu, D., Li, Y., Zhu, P. ... Wang, J. (2012). Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials. Oncology Letters, 3, 831-838. https://doi.org/10.3892/ol.2012.567
MLA
Zhang, C., Wang, J., Gu, H., Zhu, D., Li, Y., Zhu, P., Wang, Y., Wang, J."Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials". Oncology Letters 3.4 (2012): 831-838.
Chicago
Zhang, C., Wang, J., Gu, H., Zhu, D., Li, Y., Zhu, P., Wang, Y., Wang, J."Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials". Oncology Letters 3, no. 4 (2012): 831-838. https://doi.org/10.3892/ol.2012.567